Trading Animal Models for Patient-Derived Precision

Can Human Tumor Fragments Replace Mouse Studies?

Update: The NIH announced it will NO LONGER fund new studies that rely solely on animal testing! More here.

The FDA’s recent initiatives (Modernization Act 2.0 in Dec. 2022 and a 2025 roadmap) signal a major paradigm shift. Regulators now encourage New Approach Methodologies (NAMs), including human cell assays, organoids, organ-on-chip systems and AI – for IND applications. FDA leadership envisions “replacing animal testing” with human-relevant methods to improve safety predictivity and speed up drug development. This momentum raises a provocative question for biotech innovators: Could ex vivo human tumor fragments (patient-derived organoids/slices) one day stand in for mouse models in oncology R&D?

Advantages of ex vivo tumor cultures: Unlike mouse xenografts, cultured human tumor fragments preserve native 3D architecture, cellular diversity and microenvironmental cues. This human relevance can yield more predictive pharmacology: rodent models miss key human-specific drug responses (genetic variability, metabolism, immune effects) that contribute to ~90% clinical trial failures. Ex vivo platforms also work faster (days–weeks to grow cultures vs. months–years to expand PDX tumors) and enable higher throughput screening on limited tissue. Critically, they align with ethical and regulatory trends: 3D patient-derived models inherently reduce animal use and thus comply with FDA’s 3Rs principles and Modernization Act guidance. Finally, by testing each drug on a patient’s own tumor cells, these systems directly advance precision medicine. In short, ex vivo tumor platforms offer humanized, rapid, and ethical advantages over traditional mouse studies.

Key examples – evidence & progress: A growing body of work demonstrates the power of tumor-on-chip and slice models for cancer drug testing. For instance, organotypic tumor slice cultures (3D-TSC), thin slices of patient tumors maintained in vitro, have long been used to assess drug responses and are now applied to evaluate chemotherapy and even immunotherapy in intact human tissue. In a recent clinical study, drug sensitivity profiles from colorectal cancer organoids predicted patients’ progression-free survival: patients whose organoids were drug-sensitive had median PFS ~16 months vs. 9 months for organoid-resistant cases. A systematic review found 17 PDO-based studies where ex vivo drug-screen results correlated with patient outcomes, supporting PDOs as predictive biomarkers.

Other high-tech platforms push these models further. Lockhart et al. (2024) developed a 96-well microfluidic device to test hundreds of uniform tumor “cuboids” (microdissected human tumor fragments) in parallel. This system preserves each fragment’s native microenvironment and allows multi-drug dosing with minimal tissue. Similarly, Nguyen et al. (2024) report a real-time aptamer sensor that detects cytochrome-C release from microdissected tumor biopsies under drug treatment, enabling dynamic monitoring of cell death in intact human tissue. These proof-of-concept studies show not only that ex vivo tumor assays are technically feasible, but that human tumor fragments can be handled and analyzed at scale for drug screening.

Regulatory and translational challenges: Despite promise, replacing animal data with ex vivo results will require meeting stringent benchmarks. Currently, FDA still expects robust safety/efficacy data to support INDs, typically from well-characterized animal studies, though it increasingly accepts NAMs as supplements or alternatives. FDA programs (e.g. ISTAND drug-dev tools) are actively qualifying microphysiological systems for regulatory use. In fact, the FDA’s own roadmap explicitly cites “Ex vivo human tissues” (e.g. maintained organ slices) as NAMs that use real tissue architecture to flag toxicities. Agencies expect rigorous validation: ex vivo assays must demonstrate reproducibility, defined endpoints and relevance to human outcomes.

Key scientific challenges remain. Tissue heterogeneity and limited viability (often days) can limit throughput and standardization. Protocols for slicing, culture conditions, and assay readouts vary between labs, so cross-validation is needed. Moreover, ex vivo tumor models alone won’t capture systemic PK/PD; combining them with computational models (PBPK, AI) or complementary assays will be essential. Finally, regulatory acceptance hinges on demonstrating that ex vivo results would have correctly predicted past clinical outcomes. In other words, can these models de-risk drug development to the same degree as animal models did (or better)? Case studies and consortia may be required to generate the comparative data.

Looking ahead, the stage is set for a coordinated effort. Biotechs and VCs should note that human-derived tumor models are rapidly maturing into practical tools. As FDA’s recent announcement makes clear, NAMs (including tumor organoids/slices) are now being actively integrated into review processes. Early adopters will gain competitive advantage: lower R&D costs, faster timelines, and potentially safer, more efficacious drugs. To get there, however, we need dialogue between developers and regulators (e.g. submitting ex vivo data via FDA’s ISTAND/DDT programs), and investment in standardized platforms.

How ready are we to ditch mice? The answer likely lies in a phased approach: use ex vivo assays to augment and refine animal studies now (for example, to prioritize candidates or uncover human-specific toxicity) while validating their predictive power. Over time, as confidence grows and regulatory frameworks evolve, these platforms could shoulder more of the preclinical burden. We invite colleagues and partners to discuss: what benchmarks and data will convince the FDA and our industry that intact human tumor cultures can replace (or at least dramatically reduce) animal testing in oncology? The future of drug discovery may well hinge on shifting from “mice to men” in a literal sense – and that future looks closer than ever.

References: FDA guidance and recent literature emphasize the shift toward human-relevant models. Key studies illustrate the efficacy of tumor-on-chip and organoid platforms for oncology drug testing, as do FDA/NAM roadmaps.